Skip to main content

Table 6 Cumulative chronic sensory neuropathy rates in selected phase III trials involving oxaliplatin and 5-FU based combination chemotherapy

From: Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

Ref. Regimen Oxaliplatin Dose: mg/m2 Planned Oxaliplatin Dose intensity: mg/m2/wk Treatment ≥ grade 3
25 OX + FU/LVa chronotherapy Both arms: 20 days 1–5 q 3 wk 20/10.5 hr CI; peak at 4:00 pm 33.3 First line 16%
  Constant rate 20/24 hr CI    31%
26 OX + FU/LVb 125/6 hr day 1 q 3 wk 10:00 am to 4:00 pm 41.7 First line 10%
3 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 First line 18.2%
4 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 First line 18%
  IROX 85/1.5 hr day 1 q 3 wk 28.3   7%
5 FOLFOX 6 100/2 hr day 1 q 2 wk 50 First line 34%
27 FUFOX 50/2 hr days 1, 8, 15, 22 q 5 wkc 40 First line 17%
28 FUFOX 50/x hr days 1, 8, 15, 22 q 5 wkc 40 First line 25%
  CAPOX 70/x hr d 1, 8 q 3 wk 46.7   16%
17 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 Adjuvant 12%
5 FOLFOX 6 100/2 hr day 1 q 2 wk 50 Second lined 20%
29 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 Second or third linee 3%f
  1. FOLFOX: oxaliplatin and biweekly FULV2; IROX: oxaliplatin and irinotecan;
  2. FUFOX: oxaliplatin and weekly 24 hour infusional 5-FU/LV; CAPOX: capecitabine and oxaliplatin
  3. a 5-FU 600 mg/m2 and LV 300 mg/m2 daily for 5 days over 12 hr with peak at either 04:00 am or over 24 hr by constant rate infusion; b 5-FU 700 mg/m2 and LV 300 mg/m2 daily for 5 days over 12 hr with peak at 04:00 am; c after the first four cycles, oxaliplatin given every 2 weeks; d patients had previously progressed on FOLFIRI; e Grade 3–4 acute, cold-sensitive paresthesia also occurred in 3% of patients.
\